Custom service

Insect Cell based VLP Production

Baculovirus-driven assembly, at the scale that structural work needs.

Hosts: Sf9, High Five cells in suspensionVLP types: Enveloped and non-enveloped; influenza, SARS-CoV-2, HIV, RSV and custom particlesScale: 1–10 L culture; larger on request

Insect cells are the workhorse of VLP production for a practical reason: the baculovirus system expresses high levels of multiple proteins simultaneously, and VLPs are, by definition, a multi-protein assembly problem. Envelope proteins, matrix and capsid components can all be driven from one or several baculovirus constructs, and the cells assemble them into particles with mammalian-like glycosylation that yeast and bacteria cannot provide.

The workflow begins with construct design: which proteins the particle needs, whether they are best expressed from one multi-gene baculovirus or from co-infection, and where purification tags sit without disturbing assembly. Expression is optimised for multiplicity of infection and harvest time, because VLP yield peaks earlier than total protein and a late harvest collects broken particles with the good ones.

Purification is by the particle, not by the protein. Clarified harvest is concentrated and clarified again, then purified by density gradient, SEC or chromatography steps chosen for the particle's density and charge. QC measures particle count and morphology by electron microscopy, protein composition, and where relevant, antigenicity — the particle must present the conformation the immunisation or assay needs.

Insect cell VLPs serve vaccine immunogen production, antigen presentation for antibody discovery against native conformations, and structural studies where the particle, not the subunit, is the object of interest.

They are not the right system when the particle must carry mammalian-specific glycosylation patterns or when regulatory documentation requires a defined mammalian production system — those go to mammalian cell VLP production.

Each batch is delivered with TEM images and particle count, protein composition by SDS-PAGE and mass spectrometry, glycan profile summary, antigenicity measurement where a readout exists, and endotoxin for any batch intended for immunisation or in vivo use.

Service Highlights

  • Multi-protein assembly. One to four structural proteins co-expressed from baculovirus constructs, with co-infection ratios optimised per particle.
  • Mammalian-like glycosylation. Insect cell N-glycosylation supports enveloped VLPs and conformational epitopes that bacterial systems cannot form.
  • Assembly-optimised harvest. MOI and harvest time tuned to particle yield rather than total protein, since particles and broken subunits peak at different times.
  • Particle-based purification. Density gradients, SEC and chromatography selected for the particle, with intact morphology preserved.
  • EM-verified particles. Transmission electron microscopy confirms morphology and particle count for every batch.
  • Antigenicity QC. Conformational antibody or ligand binding measured on the final particle where a readout exists.

How the work runs

  1. Particle design

    Structural proteins, tags and glycosylation requirements defined; single- versus multi-baculovirus strategy decided.

  2. Baculovirus construction

    Recombinant baculoviruses generated and titre-determined by plaque assay or flow.

  3. Expression optimisation

    MOI, co-infection ratios and harvest time screened for particle yield and morphology.

  4. Preparative expression

    Suspension culture at the optimised conditions, harvested at the particle-yield peak.

  5. Purification

    Clarification, concentration, density gradient or chromatography, and sterile filtration.

  6. QC

    EM morphology and count, protein composition, glycosylation check, and antigenicity where applicable.

Specifications & timeline

Hosts
Sf9, High Five cells in suspension
VLP types
Enveloped and non-enveloped; influenza, SARS-CoV-2, HIV, RSV and custom particles
Scale
1–10 L culture; larger on request
Yield
0.1–5 mg/L purified VLP, target-dependent
QC
TEM, SDS-PAGE, glycan profile, antigenicity, endotoxin
Timeline
6–10 weeks per construct

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.